Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax

Total 125 results found. Search for [ Abbreviated New Drug Applications ]

Results 80 to 100 of 125
New Delhi, June 20, 2016
Zydus Healthcare, a subsidiary of Cadila Healthcare, on Monday said it has acquired two abbreviated new drug applications (ANDAs) from Teva Pharmaceutical in the US for an undisclosed sum.

E Kumar Sharma
June 14, 2016
The deal, which cost Dr. Reddy's $350 million, translates into around $45 million paid for each product.

BT Online
New Delhi, June 13, 2016
Shares of Amtek Auto soared over 4.91 per cent on BSE after the company reported that the automobile component maker was close to selling its profitable German unit, Tekfor, for about $700 million (Rs 4,690 crore) to a foreign buyer in order to cut its debt.

New Delhi, June 13, 2016
Shares of Dr Reddy's Laboratories surged over 1 per cent on Monday's trade after the company inked a pact with Teva Pharmaceutical and an affiliate of Allergan Plc to buy a portfolio of eight abbreviated new drug applications (ANDAs) in the US for $350 million (around Rs 2,300 crore) in cash.

P.B. Jayakumar and E. Kumar Sharma
Delhi, January 16, 2016
Since the past eight months the merged entity has been trading on the Bombay Stock Exchange, nervous investors have been asking two questions - is Shangvi's magic fading? Or, is the slump just a small hitch in Sun's glorious journey over the past one decade?

PB Jayakumar
December 4, 2015
Gleevec had made global headlines a few years ago following the Indian Patent office's decision to not allow a patent in India.

Mumbai, December 2, 2015
Alkem Laboratories plans to expand its footprint globally. It had a portfolio of 705 brands in the domestic market as on September 30.

New Delhi, October 22, 2015
The company has posted standalone net profit of Rs 614.08 crore for the quarter ended September 30, 2015 as compared to Rs 365,61 crore in the year-ago period.

BT Online
New Delhi, September 18, 2015
With the markets rising 254 points at close on the Fed's decision, here are the five stocks that were in news today.

New Delhi, September 4, 2015
\"Glenmark Pharmaceuticals Inc., USA has been granted final approval by the US Food & Drug Administration (USFDA) for Voriconazole Tablets, the therapeutic equivalent to Vfend tablets,\" Glenmark said in a BSE filing.

E. Kumar Sharma
August 5, 2015
The increase is to come into effect from 1st October and the rise seems almost immaterial to many. The current increase - at 30 per cent - may look large if seen in percentage terms but in absolute terms, it amounts to an increase of around $20,000 per ANDA.

Hyderabad, August 5, 2015
However, the fees for facility inspection of foreign companies have been reduced, which may encourage more firms to opt for audit of their facilities by the regulator.

New Delhi, July 23, 2015
Commenting on the results, Lupin Managing Director Nilesh Gupta said: Slowdown in approvals in the US dampened growth during the quarter, even as the company continues to improve on gross margins. The company remains focused on evolving its research pipeline, ensuring compliance, operational excellence and acquiring meaningful assets, he added.

New Delhi, June 22, 2015
Wockhardt is launching the product soon and will be amongst the few generic versions of this product in the market.

New Delhi, May 4, 2015
\"Glenmark will market this product upon receiving final approval of its Calcipotriene cream, 0.005 per cent, abbreviated new drug application (ANDA),\" the company said.

P.B. Jayakumar
May 18, 2015
Industry observers feel it would take a lot of effort for Wockhardt to regain its glory and it won't be easy considering the company's business mix, strategies and product portfolio.

New Delhi, April 15, 2015
Aurobindo pharma said the product has an estimated market size of $123 million for the twelve months ended February 2015.

New Delhi, April 10, 2015
Glenmark Pharmaceuticals said the approval marks its 11th oral contraceptive authorised for distribution by the US Food and Drug Administration.

PB Jayakumar
March 25, 2015
Dilip Shanghvi, the founder and promoter of Sun Pharma, outlined the growth strategy of the merged entity-with a turnover of Rs 27,856 crore at a press conference in Mumbai.

New Delhi, November 26, 2014
Ranbaxy Laboratories had sued US Food and Drug Administration (USFDA) over revoking an approval to sell generic versions of Nexium and Valcyte in the US market.

PAGES 5 OF 7  12345